Department of Medical Oncology, San Camillo-Forlanini Hospital, Circonvallazione Gianicolense 87, 00152, Rome, Italy.
Expert Opin Drug Saf. 2012 Sep;11(5):851-9. doi: 10.1517/14740338.2012.712108. Epub 2012 Aug 4.
Renal cell carcinoma (RCC) is still a challenging disease. Over the last 6 years, the use of novel targeted therapies interfering with vascularization and inhibition of other downstream pathways has revolutionized the therapy of this disease, leading to an improvement of patient outcomes. In particular, dysregulation of the vascular endothelial growth factor (VEGF) pathway and VEGF protein overexpression have proved important, as they result in increased tumor angiogenesis and RCC growth and development.
This review briefly discusses the mechanisms of action and clinical applications of pazopanib . It mainly outlines the safety and tolerability of pazopanib for locally advanced/metastatic RCC. Phase III pazopanib safety data are also indirectly compared with other standard, antiangiogenic receptor tyrosine kinase inhibitors currently used in the management of RCC.
Pazopanib is a new drug available in the oncology portfolio to treat patients with predominantly clear-cell RCC. The toxicity profile of pazopanib is comparable, but in some ways distinct, from other antiangiogenic drugs used in the treatment of RCC. Long-term data about late side effects of this treatment are awaited.
肾细胞癌(RCC)仍然是一种具有挑战性的疾病。在过去的 6 年中,新型靶向治疗药物的使用干扰了血管生成和抑制其他下游途径,彻底改变了这种疾病的治疗方法,改善了患者的预后。特别是,血管内皮生长因子(VEGF)途径的失调和 VEGF 蛋白的过度表达被证明是重要的,因为它们导致肿瘤血管生成增加以及 RCC 的生长和发展。
本文简要讨论了帕唑帕尼的作用机制和临床应用。它主要概述了帕唑帕尼治疗局部晚期/转移性 RCC 的安全性和耐受性。还间接比较了帕唑帕尼的 III 期安全性数据与目前用于 RCC 治疗的其他标准抗血管生成受体酪氨酸激酶抑制剂。
帕唑帕尼是肿瘤学组合中的一种新药,用于治疗主要为透明细胞 RCC 的患者。帕唑帕尼的毒性谱与其他用于治疗 RCC 的抗血管生成药物相似,但在某些方面有所不同。正在等待关于这种治疗方法晚期副作用的长期数据。